Vident Advisory, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Vident Advisory, LLC
- $5.7 Trillion
- Q4 2024
A detailed history of Vident Advisory, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 14,735 shares of ZNTL stock, worth $26,375. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,735Holding current value
$26,375% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
147Shares Held
65.4MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$25 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$8.63 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$8.01 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$5.86 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$5.76 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $102M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...